NASDAQ:KROS Keros Therapeutics Q2 2025 Earnings Report $11.36 +0.10 (+0.89%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$11.38 +0.02 (+0.18%) As of 10/2/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Keros Therapeutics EPS ResultsActual EPS-$0.76Consensus EPS -$1.14Beat/MissBeat by +$0.38One Year Ago EPS-$1.25Keros Therapeutics Revenue ResultsActual Revenue$0.02 millionExpected Revenue$3.83 millionBeat/MissMissed by -$3.81 millionYoY Revenue Growth+49,002.70%Keros Therapeutics Announcement DetailsQuarterQ2 2025Date8/6/2025TimeBefore Market OpensConference Call DateWednesday, August 6, 2025Conference Call Time4:00PM ETUpcoming EarningsKeros Therapeutics' Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 5, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Keros Therapeutics Earnings HeadlinesKeros Therapeutics Advances DMD Trial for KER-065, Keeping Rare Disease Upside in PlaySeptember 30 at 12:51 PM | tipranks.comKeros Therapeutics Expects $20 Million Milestone Payment From TakedaSeptember 29, 2026 | finance.yahoo.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required. | Stansberry Research (Ad)Keros Therapeutics Expects $20 Million Milestone Payment After First Patient Dosed in Takeda’s ELRiSE MF Phase 3 TrialSeptember 29, 2026 | quiverquant.comQKeros Therapeutics to Receive Additional Development Milestone Payment from Partner TakedaSeptember 29, 2026 | globenewswire.comKeros Therapeutics, Inc. (NASDAQ:KROS) Receives Average Rating of "Hold" from BrokeragesSeptember 29, 2026 | americanbankingnews.comSee More Keros Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Keros Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Keros Therapeutics and other key companies, straight to your email. Email Address About Keros TherapeuticsKeros Therapeutics (NASDAQ:KROS) is a clinical-stage biopharmaceutical company focused on discovering and developing medicines that regulate signaling within the transforming growth factor beta (TGF-β) superfamily. The company’s research is aimed at addressing diseases in which abnormal signaling affects blood-cell production, bone health, muscle function, or cardiovascular health. Keros has developed investigational ligand-trap therapies designed to modify signaling by activin and related proteins. Its pipeline has included elritercept (KER-050), an investigational therapy studied for conditions involving ineffective blood-cell production, including myelodysplastic syndromes and myelofibrosis, and cibotercept (KER-012), which was evaluated in pulmonary arterial hypertension and other disease areas. The company has also advanced KER-065, an investigational therapy intended to influence muscle and metabolic biology. Founded in 2015 and headquartered in Lexington, Massachusetts, Keros conducts its research and clinical development activities primarily in the United States while working with clinical investigators and research partners in other regions as appropriate. Its therapies remain investigational and require successful clinical testing and regulatory review before they can be marketed.View Keros Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Time to Nibble on MCD Stock After it Enters Oversold Territory?McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCorning and AT&T's $3 Billion Fiber Deal Reveals Where AI Spending Goes NextTarget's Holiday Blitz: Slashing Prices to Capture Market Share Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
